ACROBiosystems/ActiveMax® Human VEGF110 Protein, Tag Free (HPLC-verified)/20ug/VE0

价格
¥80000.00
货号:VE0
浏览量:93
品牌:ACROBiosystems
服务
全国联保
正品保证
正规发票
签订合同
商品描述
  • Synonym
    RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF
  • Source
    ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (VE0-H5212) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 136 (Accession # NP_001165097).
    Predicted N-terminus: Ala 27
    Request for sequence
  • Molecular Characterization
    Online(Ala 27 - Arg 136) NP_001165097

    This protein carries no "tag".

    The protein has a calculated MW of 12.7 kDa. The protein migrates as 18-20 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

    This product does not contain a heparin binding domain, and therefore doesn"t bind with heparin.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-HPLC.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (Cat. No. VE0-H5212) SDS-PAGE gel

ActiveMax® Human VEGF110, Tag Free (HPLC-verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-HPLC
ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (Cat. No. ) HPLC images

The purity of ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (Cat. No. VE0-H5212) was greater than 95% as determined by SEC-HPLC.

Bioactivity-ELISA
ActiveMax® Human VEGF110, Tag Free (HPLC-verified)ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (Cat. No. VE0-H5212) ELISA bioactivity

Immobilized ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (Cat. No. VE0-H5212) at 0.05 μg/mL (100 μL/well) can bind Human VEGF R1, His Tag (Cat. No. VE1-H5220) with a linear range of 4-63 ng/mL (QC tested).

Protocol
Bioactivity-Cell based assay
Human FcRn Heterodimer Protein Cell_Base

ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (Cat. No. VE0-H5212) stimulates proliferation of human umbilical vein endothelial cells (HUVEC). The EC50 for this effect is 5.06-11.59 ng/mL (Routinely tested).

Protocol
Bioactivity-Cell based assay
Human FcRn Heterodimer Protein Cell_Base

ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (Cat. No. VE0-H5212) stimulates proliferation of human umbilical vein endothelial cells (HUVEC). The EC50 for this effect is 5.06-11.59 ng/mL (Routinely tested).

Protocol
  • Amino Acid Sequence

    APMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDR

  • Background
    Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, andis a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Alternatively spliced isoforms of 110,121,145,165,183,189 and 206 amino acids in length are expressed in humans.
  • References
    • (1)Takahashi, H. and Shibuya, M., 2005, Clin Sci (Lond) 109, 227-41.
    • (2)Neufeld, G. et al., 1999, FASEB J 13, 9-22.
    • (3)Robinson, C.J. and Stringer, S.E., 2001, J Cell Sci 114, 853-65.
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

ACROBiosystems治疗性抗体的功效不仅取决于Fab片段及其与靶抗原的结合活性,还取决于Fc片段及其与关键Fc受体的相互作用。Fc片段对FcRn的结合亲和力(FCGRT&B2M)将预测抗体的半衰期,而Fc片段与FcγRIIIa(CD16a)之间的结合亲和力将影响抗体引发ADCC的能力(抗体依赖性细胞介导的细胞毒性)。因此,必须在抗体工程化过程中针对一组受体测试候选人。ACROBiosystems提供了完整的重组Fc受体蛋白集合,包括它们的常见变体,以帮助您加快mAb的开发。